Results 71 to 80 of about 367,529 (264)

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Effects of Evaporation and Body Thermal Plume on Cough Droplet Dispersion and Exposure Risk for Queuing People

open access: yesLife
The transmission of virus-containing droplets among multiple people in an outdoor environment is seldom evaluated. In this study, an Euler–Lagrange computational fluid dynamics approach was used to investigate the effects of evaporation and the body ...
Fengjiao Li   +3 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Evaluating a virtual paediatric adverse drug reaction clinic

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck   +2 more
wiley   +1 more source

NEW VIEW ON COUGH TREATMENT IN CHILDREN

open access: yesПедиатрическая фармакология, 2013
The article is dedicated to cough treatment in children as one of the most frequent causes of references to pediatricians. The authors explain mechanisms and causes of this symptom – both frequent and rare. The latter often lead to underestimation of the
Y. L. Soldatskiy   +2 more
doaj   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

open access: yes
American Journal of Hematology, EarlyView.
Kenneth I. Ataga   +8 more
wiley   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus   +4 more
wiley   +1 more source

APPLICATION OF VEGETABLE DRUGS FOR TREATING COUGH IN CHILDREN

open access: yesПедиатрическая фармакология, 2012
Phytotherapy holds a special place in the treatment of acute respiratory infections in pediatric practice. The article gives causes and mechanisms of cough in children and possibilities of its therapy using vegetable drugs.
V. V. Chernikov
doaj   +1 more source

COUGH PHYTOTHERAPY IN EARLY CHILDHOOD

open access: yesПедиатрическая фармакология, 2012
Treatment of acute respiratory infections remains one of the most pressing problems in children. Mucolytic and expectorant therapy aimed at facilitating the expectoration of sputum and improvement of the drainage function of bronchi, is an integral part ...
I. V. Davydova
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy